Finasteride for Male Pattern Hair Loss: Efficacy and Safety

Efficacy and Safety Profile

The American College of Physicians recommends finasteride 1 mg daily for treating male pattern hair loss, with approximately 2-4% more patients experiencing sexual dysfunction compared to placebo, including decreased libido, ejaculation disorders, and erectile dysfunction 1, 2
The overall incidence of sexual function disorders is not significantly different between finasteride and placebo, with a mean difference of 3.21 points on sexual function scales, compared to 1.26 points for each year of aging 1
The American Urological Association notes that finasteride 1 mg reduces PSA levels by approximately 50% after 12 months of therapy, similar to the 5 mg dose used for benign prostatic hyperplasia, which must be considered when interpreting prostate cancer screening results in men taking finasteride for hair loss 3, 2
The Endocrine Society suggests that the 1 mg dose has inconclusive evidence regarding direct fertility impact, though sexual side effects may indirectly affect fertility by impacting sexual function 1

The American Academy of Dermatology recommends initiating finasteride 1 mg daily for men aged 18-60 years with male pattern hair loss seeking medical treatment, and counseling patients on realistic expectations, including visible improvement typically beginning by 12 weeks, with maximal benefit at 1-2 years 1
The National Comprehensive Cancer Network advises planning for long-term treatment, as efficacy is maintained over 5+ years, but hair loss resumes if treatment is discontinued, and considering PSA baseline before starting in men approaching prostate cancer screening age (>40-45 years) 3, 2

The American Academy of Dermatology recommends finasteride 1 mg daily as first-line treatment for male pattern hair loss, and when combined with minoxidil, patients may achieve superior results compared to monotherapy, with no evidence of drug-drug interactions between these medications, as they work through entirely different pathways 4, 5, 6
The combination of finasteride and minoxidil is recommended as background therapy in treatment protocols for androgenetic alopecia, due to their complementary mechanisms of action, with finasteride blocking DHT conversion and minoxidil promoting hair follicle growth through vasodilation and direct follicular stimulation 4, 5, 6

Men taking finasteride 1 mg must have their PSA values doubled after 12 months of therapy when screening for prostate cancer, as finasteride reduces PSA levels by approximately 50% after 12 months 7
When using oral minoxidil, monitor for hypotension and orthostatic symptoms 7, tachycardia 4, fluid retention 5, and hypertrichosis (unwanted body hair growth) 4

Sexual adverse events, including decreased libido, ejaculation disorders, and erectile dysfunction, are uncommon after the first year of therapy, with a incidence of approximately 2-4% more patients compared to placebo, and are reversible upon discontinuation, as reported by The Journal of Urology 8, 9

The American Urological Association notes that finasteride is ineffective in patients with benign prostatic hyperplasia without prostatic enlargement, but this does not apply to male pattern hair loss treatment, which involves DHT inhibition at the hair follicle level, as studied in The Journal of Urology 8, 9

In men approaching prostate‑cancer screening age (approximately > 40–45 years), finasteride 1 mg reduces serum PSA by roughly 50 % after 12 months; consequently PSA values must be doubled for accurate interpretation, and failure to make this adjustment can result in missed prostate‑cancer diagnoses 10, 11.